Articles from Aurion Biotech, Inc.

Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the completion of patient enrollment in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration investigational regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to be the first cell therapy approved in the U.S. to treat this condition.

Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association of America (EBAA) 2026 Annual Meeting, taking place in Indianapolis, Indiana, from June 3-6 and at the American-European Congress of Ophthalmic Surgery (AECOS) 2026 European Symposium, June 11-14 in Madrid, Spain.

Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place in Boston May 11-15.

Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to be the first cell therapy approved in the U.S. to treat this condition.

Aurion Biotech, Inc. (“Aurion”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the appointment of Dr. Marjan Farid of the Gavin Herbert Eye Institute at the University of California-Irvine (UCI) as Chair of Aurion Biotech’s medical advisory board (MAB). Dr. Farid is a distinguished cornea, cataract and refractive surgeon, a global educator and researcher, and Chair of the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS).

Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that the Company is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 609 organizations across 58 sectors and regions. Aurion Biotech was named Number 4 in the Medicines, Therapeutics, and Pharmaceuticals category.

Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO).

Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced topline data from its Phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy product candidate for the treatment of corneal edema secondary to corneal endothelial dysfunction.